PPARG and chronic myelogenous leukemia, BCR-ABL1 positive: Target of PPARγ agonists in CML are quiescent stem cells, thereby decreasing transcription of STAT5 (103).The combination PPARγ agonists plus imatinib has been tested in cases of insufficient molecular response in chronic myeloid leukemia (CML), although PPARγ agonists have no monoactivity in CML, and imatinib had no sufficient monoactivity.